Concord Biotech gains 6% on USFDA nod for drug with $30 million US market opportunity
Shares of Concord Biotech Ltd. are trading higher by 6% on Wednesday, June 3, after the company received approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. Mycophenolate mofetil is an immunosuppressant used to prevent organ rejection in adult…
